Navigation Links
A Stage IV Malignant Melanoma Drug That Increases Overall Survival Would Earn a Higher Patient Share in the U.S. Than in Europe

Ipilimumab Will Earn Decision Resources' Clinical Gold Standard for Stage IV Malignant Melanoma in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a drug for treating stage IV malignant melanoma that can increase median overall survival when compared with standard of care dacarbazine (Bedford Laboratories' DTIC-Dome, generics) would earn a higher patient share in the U.S. (60 percent) than in Europe (40 percent), according to surveyed U.S. and European oncologists.

The new report entitled Malignant Melanoma (Stage IV): Emerging Therapies Must Increase Overall Survival over Dacarbazine to Attain High Patient Share finds that clinical data and the opinions of interviewed thought leaders indicate that Bristol-Myers Squibb/Medarex's ipilimumab has advantages over dacarbazine in the attribute of median overall survival. Following its approval in 2010 for the indication, ipilimumab will earn Decision Resources' proprietary clinical gold standard for stage IV malignant melanoma from 2012 to 2017.

"Ipilimumab has competitive advantages in efficacy and has been shown, in combination with dacarbazine, to almost double median overall survival when compared to Schering-Plough's Temodar, our clinical gold standard in 2008 for stage IV malignant melanoma," said Decision Resources Analyst Karen Pomeranz, Ph.D. "According to oncologists we surveyed, overall survival is the highest-weighted end point for stage IV malignant melanoma, which further stresses the significance of ipilimumab's achievement in increasing overall survival."

About the Report

Malignant Melanoma (Stage IV): Emerging Therapies Must Increase Overall Survival over Dacarbazine to Attain High Patient Share is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                            Decision Resources, Inc.
    Christopher Comfort                           Elizabeth Marshall
    781-296-2597                                  781-296-2563             

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Previstage(TM) GCC to be presented at ASCO GI
2. First NxStage Home Hemodialysis Patients Celebrate Five-Year Anniversary
3. Celebrity Mental Health Musings Take Center Stage as Psych Central Adds New Blog
4. Early stage, HER2-positive breast cancer patients at increased risk of recurrence
5. Vitamin B1 could reverse early-stage kidney disease in diabetes patients
6. Broccoli compound targets key enzyme in late-stage cancer
7. Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
8. NxStage(R) Ranked 14th Fastest Growing Company in North America on Deloittes 2008 Technology Fast 500
9. Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients
10. Cardiff scientists study acute infection in end-stage kidney disease patients
11. Long-Term Results of VisionCares Implantable Telescope for End-Stage Macular Degeneration Published in the American Journal of Ophthalmology
Post Your Comments:
(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
Breaking Medicine Technology: